Belgium· BE-AMP-SAM663138-00
Rystiggo 140 mg/ml
A rozanolixizumab product containing rozanolixizumab, registered in Belgium by UCB Pharma. The same ATC class is registered in 7 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Rozanolixizumab is registered in 7 of 19 countries.
Countries holding a registration under ATC L04AL02 (rozanolixizumab), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 5 of them publish a price we can compare per daily dose
Rozanolixizumab · ATC L04AL02
7 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Rozanolixizumab
- Manufacturer
- UCB Pharma
- Country
- Belgium (BE)
- ATC code
- L04AL02
- ATC class
- Rozanolixizumab
- Defined daily dose
- 80 mg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb4873055
- be_apb7746860
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Rozanolixizumab in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaRYSTIGGOUCB Pharma SA, Brusel
- SwitzerlandRystiggo 280 mg/2 ml, solution injectableUCB-Pharma SA
- SwedenRystiggo 140 mg/ml Injektionsvätska, lösningUCB Pharma S.A.
- SpainRYSTIGGO 140 MG/ML SOLUCION INYECTABLEUcb Pharma
- IcelandRystiggoUCB Pharma S.A.*
- PolandRystiggoUCB Pharma S.A.
- United StatesRYSTIGGOUCB, Inc.
- United KingdomRystiggo 280mg/2ml solution for injection vialsUCB Pharma Ltd
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Rystiggo
- Liechtenstein · Rystiggo
- Norway · Rystiggo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/807b6d71-ff1c-4623-8621-0dd69b8bbdd4 GET /v1/drugs/807b6d71-ff1c-4623-8621-0dd69b8bbdd4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Rystiggo 140 mg/ml",
"name_fr": "Rystiggo 140 mg/ml",
"name_nl": "Rystiggo 140 mg/ml",
"amp_code": "SAM663138-00",
"strengths": [
"140.0000",
"140.0000",
"29.0000"
],
"pack_count": 1,
"substances": [
"Rozanolixizumab",
"Proline",
"Polysorbate 80"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Rozanolixizumab",
"authorisation_numbers": [
"EU/1/23/1780/002"
]
}See everything about rozanolixizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.